Press release
Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama
Carlyle and co-investors including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund (“Merck GHI”), McKesson Ventures, Northpond
About this update from The Carlyle Group Inc.
[{"type":"text","content":"\n\nCarlyle and co-investors including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund (“Merck GHI”), McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners to acquire majority stake in Saama\n\n\nInvestment to accelerate development of Saama’s AI-driven data management and analytics capabilities to redefine the drug development paradigm\n\n\n CAMPBELL, Calif.--(BUSINESS WIRE)--\nSaama Technologies, Inc. (“Saama”) today announced funds led by global investment firm Carlyle (NASDAQ: CG) have made a strategic growth investment and will acquire a majority stake in the Company. A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund (“Merck GHI”), McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.\n\nThe partnership will allow Saama to accelerate its strategic initiatives, including expanding its go-to-market capabilities and further investing in AI research and development.\n\nSaama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies. As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics. LSAC’s pre-trained AI embedded smart applications have the ability to learn the complex patterns among clinical data and provide predictive insights to accelerate the clinical research process across a variety of domains and therapeutic areas.\n\n“The life sciences industry is experiencing a massive shift in strategic approaches to accelerating drug development as a result of the COVID-19 pandemic, and AI-driven analytics solutions like Saama’s LSAC are at the forefront. These solutions’ role in successfully enabling the delivery of COVID-19 vaccines and therapies to patients in mere months was the litmus test for the future of drug development,” said Suresh Katta, Founder and CEO, Saama Technologies. “This investment by Carlyle and leading healthcare-focused venture funds reflects the value they see in Saama’s leadership of this new era and the promise offered by our state-of-the-art solutions.”\n\n“The life sciences industry is at an exciting crossroads, poised to adopt and integrate soph...